News

March 22nd - Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)

December 7th - Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 Into Clinical Trials For Adult ADHD

December 5th - Euthymics Featured in BioCentury Emerging Company Profile

November 9th - Euthymics Bioscience, Inc. Appoints Dr. Randall Marshall, Leader in the Psychiatric Field, as Executive Director, Medical Affairs.

July 5th - Euthymics’ Lead Product Gains Generic Name, EB-1010 Now Called Amitifadine

June 28th - Euthymics Bioscience, Inc. Appoints Biotech Industry Veteran Thomas A. Shea as CFO and Announces Additional Senior Management Appointments

March 14th - Euthymics Bioscience Initiates TRIADE Trial for Major Depression

March 9th - Euthymics Bioscience Increases Series A Financing to Advance Second Program

December 8th - Euthymics Bioscience, Inc. Presents Phase II Data For EB-1010 In Major Depression At ACNP Annual Meeting

November 18th - Euthymics Bioscience, Inc. Appoints Biotech Industry Veteran Walter Piskorski As Vice President, Technical Operations

November 4th - Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich To Board Of Directors

August 18th - Euthymics Bioscience, Inc. Appoints Industry Veterans Dr. Pierre Tran, Joan Manthis And William Pappafotopoulos To Senior Management Team

July 22nd - Euthymics Bioscience, Inc. Closes $24 Million Series A Financing And Completes Acquisition Of Dov Pharmaceutical